엔트라다 테라퓨틱스(TRDA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $6.75 (-2.17%), 시가총액 $0.24B, 52주 최저~최고 $5.02 ~ $16.03.
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated
엔트라다 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
엔트라다 테라퓨틱스의 현재 주가는 $6.75 (-2.17%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
엔트라다 테라퓨틱스의 시가총액은 약 $0.24B입니다.
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have